AdAlta

next generation protein therapeutics

i-bodies – a new class of protein therapeutics to treat human disease

October 2017

Sam Cobb, CEO and Managing Director

AdAlta Limited (ASX:1AD)

s.cobb@adalta.com.au

Disclaimer

Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital.

This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the investment objectives, financial situation and particular needs of the investor. Before making any investment in AdAlta, the investor or prospective investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary.

This presentation may contain forward-looking statements regarding the potential of the Company's projects and interests and the development and therapeutic potential of the company's research and development. Any statement describing a goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company's research and development projects and interests (where applicable) will receive regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research and development programs referred to in this presentation.

Corporate and investment summary

- A drug discovery and development company using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.
- **Investment highlights**
  - Initial focus on treating fibrosis – high unmet medical need
  - Advanced lead fibrosis drug candidate AD-114 with significant pre-clinical validation
  - Fully funded for phase 1 development of lead fibrosis drug and i-body pipeline
  - Orphan drug designation USA FDA
  - Early commercialisation potential
  - Experienced team with strong track record of drug development and ability to deliver

Financial position

Key Financial Details	
ASX code	1AD
Share price (16 October 2017)	AU$0.24
Market capitalisation	AU$24.3m
Shares on issue*	101,257,434
Escrowed shares (August 2018)	24,000,000
Options on issue	969,427
Current cash (30 September 17)	AU$6.87m
Trading range (since listing)	AU$0.325 to $0.165
Average daily volume	32,201

Major Shareholders	%
Yuuwa Capital LP	53.39
Platinum Asset Management	8.05
Citycastle Pty Ltd	5.25
La Trobe University	3.00
National Nominees Limited	2.14
Other shareholders	28.17
Total	100%



AdAlta

Fibrosis: unmet medical need with multiple indications

- Developing i-bodies as improved therapies for the treatment of fibrosis
  - a condition that is prevalent in 45-50% of all diseases
- Fibrosis can occur in many tissues of the body as a result of inflammation or damage
  - it can result in scarring of vital organs causing irreparable damage and eventual organ failure
- AdAlta's initial focus is on lung fibrosis

Collectively fibrosis represents a large unmet clinical need



AD-114 prevents lung fibrosis in disease models

Extensive pre-clinical AD-114 studies have demonstrated positive *in vitro* (in the lab) and *in vivo* (in animals) data



Normal lung tissue



IPF lung tissue
(lung disease mouse model)



IPF lung tissue + AD-114 dosed for 21 days
(lung disease mouse model)

AD-114 reduces collagen content and inflammatory cell infiltration and demonstrates a similar architecture to that of the normal lung in the Bleomycin mouse model

AD-114 has broad application in treating fibrosis

AdAlta data shows that AD-114 can improve fibrosis across a range of fibrotic diseases

- **LUNG:** Idiopathic Pulmonary Fibrosis
- **EYE:** Wet Age Related Macular Degeneration
- **LIVER:** NASH
- **SKIN:** Hypertrophic scar
- **KIDNEY:** Chronic Kidney Disease

AD-114 has demonstrated broad anti-fibrotic and anti-inflammatory effects in several animal models of disease and with human tissues

AD-114 has demonstrated safety in non-human primate studies



AdAlta

Global market interest in fibrosis treatments

Fibrosis assets acquired at an early stage – typically based on Phase I results

Date	Company	Target	Acquired by	Deal value (US$)	Deal commentary
Sep-15	Adheron Therapeutics	SDP051	Roche	$105M upfront, plus $475M in milestones	SDP-51 at end of Phase I for IPF
Aug-15	Promedior	PRM-151	BMS	$150m upfront + $1.25B	Phase II IPF and myelofibrosis
Nov-14	Galecto Biotech AB	TD139	BMS	$444M	Option to acquire at end of clinical POC (no later than 60 days following Ph 1b for IPF completion)
Aug-14	Intermune	Esbriet / Pirfenidone	Roche	$8.3B	Approval in Europe / Japan, phase III in the US
Jun-13	MicroDose Therapeutx	MMI0100	Teva Pharmaceuticals	$40M upfront $125M milestones	MMI0100 was in pre-clinical development
Mar-12	Stromedix	STX100	Biogen Idec	$75M upfront $487.5M milestones	End of phase I for IPF
Jul-11	Amira / BMS	BMS-986020	BMS	$325M upfront $150M milestones	End of phase I for IPF

Source: Medtrack Pharma Intelligence, Informa (all IPF deals since 2011)

IPF Phase II readouts generate $1.4billion market value

FibroGen

- (NASDAQ:FGEN)
- $869 million added to its market cap on announcement (7 August 2017) of meeting primary endpoint in Phase IIb study
- Pamrevlumab (FG-3019) 103 patients 48 weeks

Galápagos

- (Euronext:GLPG; NASDAQ:GLPG)
- $555 million added to market cap on announcement (9 August 2017) exploratory Phase IIa data
- FLORA trial had 23 IPF patients:17 drug, 6 placebo for 12 weeks

AdAlta business model – strategy to create value

i-body technology platform and library

Pharma & biotech partnerships

Revenues: Upfronts, FTEs, milestones & royalties

In-house pipeline of drug candidates

Invest up to key value inflection point

Licence to pharma

Revenues: major upfronts + milestones & royalties

i-bodies new drug class

Potential in multiple disease indications

Long loop that enables access to novel drug targets

Market benchmarks

Fibrosis lead AD-114	adheron THERAPEUTICS Sep-15 acquired by Roche $105m + $475m milestones phase I asset	Promedior Aug-15 acquired by BMS $150m + $1.25b milestones phase IIa asset	Galecto Biotech AB Nov-14 acquired by BMS $444m phase I asset
Next gen antibodies	arGEN-X April-16 with Abbvie $40m upfront + $645m milestones & royalties	pieris PHARMACEUTICALS May -17 with AZ $58m upfront + $2.1b milestones & royalties	Ablynx July-17 with Sanofi €31m upfront + €2.4b milestones & royalties
GPCRs	HEPTARES therapeutics Acquired Feb-15 by Sosei $400m Phase Ib asset + 7 pre-clinical leads	receptos Acquired by Celgene July-15 $8b Ph III, Ph II and GPCR platform	Ablynx April-16 with Boehringer €8m payment for Ph1 GPCR nanobody + €125m milestones & royalties

AD-114 development: key milestones



AdAlta

Expected news flow next 12 months

H1 2017	✓	Orphan Drug Designation (US FDA)
	✓	Presentation at partnering meetings including Biotech Showcase 2017, San Francisco
	✓	Data available from AD-114 NASH animal studies
	✓	Manufactured material for toxicology testing available
H2 2017	✓	Strengthened eye fibrosis, funded by NHMRC Development Grant with Melbourne University, and lung data, funded by Innovation Connection Grant with Alfred Health
	✓	Completion of additional pre-clinical animal models in diseased of the lung, kidney, skin; strengthening broad anti-fibrotic data package of AD-114
	✓	AD-114 pharmacokinetics (half life) and toxicology results in 3 non-human primate studies
	✓	Presentation of AD-114 data at multiple fibrosis conferences
H1 2018	▶	Update on manufacturing
	▶	4 week NHP toxicology study
	▶	Publication of lung data
H2 2018	▶	Phase I study with AD-114

AdAlta summary

- IPO August 2016 raised $10M to meet major milestones: phase I clinical trials of AD-114 in lung fibrosis and development of i-body pipeline
- Initial focus on treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases - high unmet clinical need
- AD-114 has significant pre-clinical validation demonstrating broad anti-fibrotic and anti-inflammatory effects as well as safety
- AD-114 orphan drug designation with FDA for treatment of IPF
- Powerful proprietary technology platform to develop a pipeline of i-bodies for the treatment of a wide range of human diseases

Early commercialisation opportunity, with experienced management and Board to drive AD-114 development and secure technology platform partnerships / product licensing deals